BioDelivery Sciences International, Inc. (BDSI) is engaged in the commercialization of therapeutics for patients with chronic conditions. The company has a versatile portfolio of differentiated pain and neurology product line. The company’s pipeline product portfolio includes treatments for chronic pain, acute migraine, and opioid-induced constipation.
The price of BDSI stock during the regular trading on February 11, 2022, was $3.64 with a 1.62% drop. At last check in the premarket on February 14, 2022, the stock rocketed by 51.3%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BDSI: Events and Happenings
On February 14, 2022, BDSI updated about its entry into a definitive combination contract with Collegium Pharmaceutical, Inc. Both the companies agreed upon the acquisition of 100% outstanding shares of BDSI at the rate of $5.60 per share. The total equity value of the transaction is approximately $604 million. The agreement had been approved by the BoDs of both companies.
On January 20, 2022, BDSI reported that it estimated the total net revenues of 2021 and BELBUCA net sales to attain the high end of its earlier guidance range, and 2021 EBITDA to come in above its former guidance range. On December 20, 2021, BDSI informed about the issuance of opinion in favor of the company by the US District Court of Delaware. The court has given the verdict in the company’s patent litigation against Alvogen Group, Inc. filed an Abbreviated New Drug Application for the company’s BELBUCA product.
BDSI: Key Financials
On November 3, 2021, BDSI released its unaudited financial results for the third quarter ended September 30, 2021. Some of the key points are discussed below.
Revenue
Net revenue in Q3 2021 was $41.1 million corresponding to $39.4 million in the same period of 2020. The net revenue of the company increased by 4.2% over the yearly period. The company missed the analysts’ estimates of by $944.2 thousand.
EPS
Basic and diluted net income per share in the Q3 2021 was $6.7 million or $0.07 versus $9.4 million or $0.09 in the same period of 2020. The EPS decreased over the yearly period. The company beat the analysts’ estimated EPS by $0.02 per share. third quarter of 2021 was per share, compared to GAAP net income of per share, in the third quarter of 2020.
On September 30, 2021, BDSI announced hosting a virtual ELYXYB Investor Day on October 14, 2021.
Conclusion
BDSI stock is 15% down the previous year and 3% up the past six months period. The latest premarket stock surge is due to the company’s announcement of the acquisition of all of its outstanding shares by Collegium. As the company is approaching its earnings announcement, it expects a revenue of $42.06 million and EPS of $0.04 per share.
